Real world outcomes of patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated in 1l with lenvatinib 24 mg: an international multicenter real-world study in europe and canada | Synapse
August 26, 2024
Real world outcomes of patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated in 1l with lenvatinib 24 mg: an international multicenter real-world study in europe and canada
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)